| Overview |
| bs-13448R-Cy5.5 |
| HBEBP2/GLYCTK Polyclonal Antibody, Cy5.5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Mouse |
| Human, Rat |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human HBEBP2/GLYCTK |
| 251-350/523 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 132158 |
| Cytoplasm |
| CG9886 like; GLCTK_HUMAN; Glycerate kinase; Glyctk; GLYCTK1; HBeAg binding protein 2; HBeAg binding protein 4; HBeAg-binding protein 4; HBeAgBP4A; HBEBP2; HBEBP4. |
| GLYCTK is a 523 amino acid protein that is expressed as seven isoforms which are present throughout the body. Localized to the cytoplasm and the mitochondrion in an isoform-specific manner, GLYCTK functions to catalyze the ATP-dependent conversion of (R)-glycerate to 3-(R)-glycerate, thereby playing an important role in neural and skeletal muscle systems. Defects in the gene encoding GLYCTK are the cause of D-glyceric acidemia, an inborn error of amino acid metabolism that is best described as nonketotic hyperglycinemia and is characterized by the excretion of D-glyceric acid in the urine. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz